Untitled

HealthTrust presents…“Direct Oral Anticoagulants in Liver Disease: Stirring the Clotroversy”

**Due to technical issues encountered with WebEx, this session was rescheduled from the original date of  February 7.**

Download the content.

Please Note: Continuing education credit is only available to those attending the session live. CE credit is not available when accessing the program on demand.

Direct oral anticoagulants (DOACs) are first line therapy for most thromboembolic disease states including nonvalvular atrial fibrillation and venous thromboembolism. However, patients with liver disease and cirrhosis were excluded from all pivotal randomized controlled trials assessing the efficacy and safety of DOACs. Their efficacy and safety remain largely unknown in this patient population. Future trials are needed to further define the efficacy, safety and possible dose adjustments of DOACs in patients with advanced liver disease (especially in those with Child-Pugh class C). The presenter will provide an overview of current literature for the use of DOACs in advanced liver disease. Specifically, for which subsets of populations that the data is the strongest.

Learning Objectives for Pharmacists & Nurses   |  At the end of this session, participants should be able to:

1. Recall the pathophysiology of chronic liver disease and its relationship to both elevated risk of thromboembolic events and bleeding.
2. Identify the pharmacokinetics of key direct oral anticoagulants (DOACs) and their relation to the effects of chronic liver disease.
3. Recognize which subgroups of patients with chronic liver disease have data for the safe and efficacious use of direct oral anticoagulants (DOACs) in thromboembolic conditions.

Presenter:

Gregory Taylor, PharmD  |  PGY-2 Pharmacy Resident  |  Princeton Baptist Medical Center

Target Audience: Pharmacists & Nurses

CE Credit: Approved for Pharmacists & Nurses

This program is approved for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of this program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this activity is 0863-9999-24-004-L01-P. The activity is approved for 1 hour (.1 CEUs) of continuing education credit for pharmacists and nurses who attend the webinar and complete the online evaluation. Pfiedler Education is a division of AORN, provider approved by the California Board of Registered Nursing, Provider Number CEP13019, for 1 contact hour. 1.0 contact hours approved for Nurses.

Note about CE credit: If you plan to obtain credit for a live session, stay until the end of the presentation to receive the verification code you will need to obtain the continuing education credit. CE credit is individual. No group credit is available. Each person must register for a webinar and attend the webinar in its entirety in order to receive an email after the event with instructions on how to apply for continuing education credit. Attendees should not share the code or forward the email to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.